An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CFTM 1 Source: ERJ Open Res, 6 (4) 00395-2020; 10.1183/23120541.00395-2020 Year: 2020
Pharmacological treatment of the biochemical defect in cystic fibrosis airways Source: Eur Respir J 2001; 17: 1314-1321 Year: 2001
Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis Source: Eur Respir J 2002; 19: 294-302 Year: 2002
Potential therapeutic use of 12-Lipoxygenase inhibitors in the treatment of mucus overproduction in cystic fibrosis Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease Year: 2009
Channelopathies in bronchiectasis Source: Eur Respir Mon 2011; 52: 150-162 Year: 2011
Targeting CFTR as a therapy for cystic fibrosis Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010
ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020 Year: 2020
Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice Source: Eur Respir J 2011; 37: 72-78 Year: 2011
Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study Source: Eur Respir J, 59 (2) 2100746; 10.1183/13993003.00746-2021 Year: 2022
Cystic fibrosis transmembrane conductance regulator pharmacotherapy Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=88 Year: 2006
Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration Source: Eur Respir J, 59 (2) 2100185; 10.1183/13993003.00185-2021 Year: 2022
Exercise reduces airway sodium ion reabsorption in cystic fibrosis but not in exercise asthma Source: Eur Respir J 2011; 37: 342 Year: 2011
First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers Source: ERJ Open Res, 7 (1) 00447-2020; 10.1183/23120541.00447-2020 Year: 2021
Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis Source: Eur Respir Rev 2013; 22: 58-65 Year: 2013
The effect of CFTR modulators on CT outcomes in cystic fibrosis Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019
Combined pirfenidone, proton pump inhibitor and N-acetylcystein (PINPOINT) in IPF: Preliminary results Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013
Pre-clinical evaluation of a novel and selective PI3K δ/gamma inhibitor in pulmonary fibrosis Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles Source: ERJ Open Res, 5 (2) 00082-2019; 10.1183/23120541.00082-2019 Year: 2019
Lack of therapeutic potential for topical metformin in treatment of airway secretion dehydration in cystic fibrosis Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease Year: 2009
Evaluation of novel LOXL2-selective inhibitors in models of pulmonary fibrosis Source: International Congress 2017 – Cellular signalling pathways in pulmonary fibrosis Year: 2017